Your browser doesn't support javascript.
loading
Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19.
Vogelzang, Erik H; Loeff, Floris C; Derksen, Ninotska I L; Kruithof, Simone; Ooijevaar-de Heer, Pleuni; van Mierlo, Gerard; Linty, Federica; Mok, Juk Yee; van Esch, Wim; de Bruin, Sanne; Vlaar, Alexander P J; Seppen, Bart; Leeuw, Maureen; van Oudheusden, Anne J G; Buiting, Anton G M; Jim, Kin Ki; Vrielink, Hans; Swaneveld, Francis; Vidarsson, Gestur; van der Schoot, C Ellen; Wever, Peter C; Li, Wentao; van Kuppeveld, Frank; Murk, Jean-Luc; Bosch, Berend Jan; Wolbink, Gerrit-Jan; Rispens, Theo.
Afiliación
  • Vogelzang EH; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, 1056 AB Reade, Amsterdam, the Netherlands.
  • Loeff FC; Department of Medical Microbiology and Infection Control, Amsterdam University Medical Center, Location Academic Medical Center, 1105 AZ Amsterdam, the Netherlands.
  • Derksen NIL; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, 1066 CX Amsterdam, the Netherlands.
  • Kruithof S; Biologics Laboratory, Sanquin Diagnostic Services, 1066 CX Amsterdam, the Netherlands.
  • Ooijevaar-de Heer P; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, 1066 CX Amsterdam, the Netherlands.
  • van Mierlo G; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, 1066 CX Amsterdam, the Netherlands.
  • Linty F; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, 1066 CX Amsterdam, the Netherlands.
  • Mok JY; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, 1066 CX Amsterdam, the Netherlands.
  • van Esch W; Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, 1066 CX Amsterdam, the Netherlands.
  • de Bruin S; Sanquin Reagents, 1066 CX Amsterdam, the Netherlands.
  • Vlaar APJ; Sanquin Reagents, 1066 CX Amsterdam, the Netherlands.
  • Seppen B; Department of Intensive Care Medicine, Amsterdam University Medical Center, Location Academic Medical Center, 1105 AZ Amsterdam, the Netherlands.
  • van Oudheusden AJG; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, 1056 AB Reade, Amsterdam, the Netherlands.
  • Buiting AGM; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, 1056 AB Reade, Amsterdam, the Netherlands.
  • Jim KK; Department of Medical Microbiology and Immunology, Elisabeth-TweeSteden Hospital, 5042 AD Tilburg, the Netherlands.
  • Vrielink H; Department of Medical Microbiology and Immunology, Elisabeth-TweeSteden Hospital, 5042 AD Tilburg, the Netherlands.
  • Swaneveld F; Department of Medical Microbiology and Infection Control, Amsterdam University Medical Center, Location Academic Medical Center, 1105 AZ Amsterdam, the Netherlands.
  • Vidarsson G; Departments of Medical Microbiology, Jeroen Bosch Hospital, 5223 GZ 's Hertogenbosch, the Netherlands.
  • van der Schoot CE; Department of Transfusion Medicine, Sanquin Blood Bank, 1066 CX Amsterdam, the Netherlands.
  • Wever PC; Department of Transfusion Medicine, Sanquin Blood Bank, 1066 CX Amsterdam, the Netherlands.
  • Li W; Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, 1066 CX Amsterdam, the Netherlands.
  • van Kuppeveld F; Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, 1066 CX Amsterdam, the Netherlands.
  • Murk JL; Departments of Medical Microbiology, Jeroen Bosch Hospital, 5223 GZ 's Hertogenbosch, the Netherlands.
  • Bosch BJ; Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, 3584 CL Utrecht, the Netherlands; and.
  • Wolbink GJ; Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, 3584 CL Utrecht, the Netherlands; and.
  • Rispens T; Department of Medical Microbiology and Immunology, Elisabeth-TweeSteden Hospital, 5042 AD Tilburg, the Netherlands.
J Immunol ; 205(12): 3491-3499, 2020 12 15.
Article en En | MEDLINE | ID: mdl-33127820
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infections often cause only mild disease that may evoke relatively low Ab titers compared with patients admitted to hospitals. Generally, total Ab bridging assays combine good sensitivity with high specificity. Therefore, we developed sensitive total Ab bridging assays for detection of SARS-CoV-2 Abs to the receptor-binding domain (RBD) and nucleocapsid protein in addition to conventional isotype-specific assays. Ab kinetics was assessed in PCR-confirmed, hospitalized coronavirus disease 2019 (COVID-19) patients (n = 41) and three populations of patients with COVID-19 symptoms not requiring hospital admission: PCR-confirmed convalescent plasmapheresis donors (n = 182), PCR-confirmed hospital care workers (n = 47), and a group of longitudinally sampled symptomatic individuals highly suspect of COVID-19 (n = 14). In nonhospitalized patients, the Ab response to RBD is weaker but follows similar kinetics, as has been observed in hospitalized patients. Across populations, the RBD bridging assay identified most patients correctly as seropositive. In 11/14 of the COVID-19-suspect cases, seroconversion in the RBD bridging assay could be demonstrated before day 12; nucleocapsid protein Abs emerged less consistently. Furthermore, we demonstrated the feasibility of finger-prick sampling for Ab detection against SARS-CoV-2 using these assays. In conclusion, the developed bridging assays reliably detect SARS-CoV-2 Abs in hospitalized and nonhospitalized patients and are therefore well suited to conduct seroprevalence studies.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas de la Nucleocápside / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales / Formación de Anticuerpos Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunol Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas de la Nucleocápside / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales / Formación de Anticuerpos Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunol Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos